Whom You Know: Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Wednesday, August 2, 2023

Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

AI demonstrated high accuracy, reduced non-diagnostic outputs, and identified HFpEF patients with worse outcomes.

Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published today in JACC Advances.1

The study, presented at the American Society of Echocardiography Annual Scientific Session, demonstrates the platform could improve the diagnosis, management, and outcomes of a condition that currently often goes undetected, or requires additional invasive procedures to confirm.

The study found AI could improve the diagnosis, management, and outcomes of HFpEF; a deadly form of heart failure that often goes undetected. (PRNewsfoto/Ultromics)

AI had fewer non-diagnostic outputs compared to HFA-PEFF and H2FPEF, correctly reclassifying 515 (73.5%) of patients and 571 (73.6%) of patients, respectively. (PRNewsfoto/Ultromics)

Ultromics' EchoGo® Heart Failure accurately detected HFpEF and provided fewer non-diagnostic outputs than current clinical scores, using just the routinely acquired A4C view from a transthoracic echocardiographic (TTE). The novel technology, which was recently granted clearance and Breakthrough Device designation by the FDA, identifies radiomic signatures of disease that are not evident to the human eye.

Senior study author, Patricia A. Pellikka, M.D, Vice Chair in the Department of Cardiovascular Medicine at Mayo Clinic, said: "HFpEF can be difficult to detect, but left undetected and untreated, can result in hospitalization and mortality. As the first AI platform cleared to detect the condition, EchoGo® Heart Failure can fill a significant unmet need."

"With more than 32 million people living with HFpEF, and the incidence increasing, clinicians will benefit from having another means to recognize this disease."

Based on the AI findings, patients could potentially be started on medications to treat their condition earlier than if they had to wait for an invasive diagnostic assessment of the disease.

The AI model was trained and developed on 6,756 patients who underwent a comprehensive TTE at Mayo Clinic in Rochester, Minnesota, between January 2009 to December 2020. It was then independently tested in geographically distinct areas within Mayo Clinic enterprise System sites across the United States, on a dataset that included 1,284 patients.

EchoGo® Heart Failure demonstrated high sensitivity and specificity, detecting 87.8% of patients who had HFpEF, and 81.9% of patients that did not.1 These results exceed what is usually observed in routine clinical practice.

It was also able to assign a correct diagnosis to 74% of patients who had returned non-diagnostic results on the commonly used HFA-PEFF and H2FPEF clinical scores.1 This improvement could translate to more patients receiving accurate and timely diagnoses and management.

During the follow-up period of up to 5 years, 444 patients died, highlighting the poor outcomes associated with HFpEF.1 The AI model was able to identify patients with worse survival, demonstrating its capacity to meaningfully improve patient outcomes.

Ross Upton, PhD, CEO and Founder of Ultromics, said: "Our research demonstrates the tremendous potential of AI in revolutionizing the detection of HFpEF. EchoGo® Heart Failure's exceptional discrimination capabilities combined with its ability to identify patients with higher mortality risks holds great promise for improving patient outcomes and enabling faster access to treatment."

"In a large number of cases, diagnostic data are often missing or discordant, making HFpEF detection challenging. AI can enhance echocardiography capabilities to help practices overcome the cumbersome intricacy of diastolic assessment. It is particularly useful for clinical centers that lack the time, resources, or expertise to perform comprehensive, diagnostic-quality, assessments."

By streamlining the screening process for this complex clinical syndrome, EchoGo® Heart Failure paves the way for more patients to receive the care they need sooner, potentially preventing more severe outcomes, and reducing HFpEF's significant burden on patients and healthcare.

Ultromics remains committed to advancing AI technology to transform cardiovascular healthcare. The groundbreaking findings from this study underscore the company's dedication to empowering healthcare professionals with tools that overcome existing bottlenecks and enhance patient care.

For more information on EchoGo® Heart Failure, visit Ultromics.com

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

The study was approved by the Institutional Review Boards of Mayo Clinic, USA and St. George's University Hospitals, NHS Foundation Trust, UK, and supported by a grant from the American Society of Echocardiography (ASE).

References:

1 - Akerman AP, Porumb M, Scott CG, et al. Automated Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction using Artificial Intelligence. JACC Advances, 2023:100452.

About Ultromics:

Ultromics is a pioneer in advanced heart failure detection. The ground-breaking platform, EchoGo ®, is transforming the way heart failure is diagnosed using artificial intelligence and cardiac ultrasound as a modality. The technology empowers clinicians to make precise, efficient, and accurate assessments of heart failure, leveraging the largest known heart disease outcomes dataset in echocardiography, accurately interpreting echocardiograms and predicting cardiac outcomes. The technology has been built in collaboration with Mayo Clinic and NHS England, and has over $50 million raised capital to support continued innovation with the likes of Blue Venture Fund, Optum Ventures, Oxford Science Enterprises, and GV. They are backed by the largest US health insurance firms with 4 FDA clearances. Ultromics' mission is to stop heart failure in its tracks with its precision detection platform. https://www.ultromics.com

Recent Testimonials by Brand Ambassadors on their Experience with Whom You Know

"I work with Peachy Deegan because she's prolific at what she does. She's a hard worker, she's thoughtful and she's tasteful at what she writes which is very important. Peachy gets the facts correct, and just that alone is worth its weight in gold."

-Edward Tricomi, Master Stylist and Owner of Warren-Tricomi
https://warrentricomi.com/

"No one has yet to express their taste for our cuisine better than Peachy Deegan on Whom You Know. Thank you for transforming our flavor into words, unlike any other before.
Sometimes WHOM YOU KNOW, really makes a difference and Ammos Estiatorio is grateful to know Peachy Deegan!"
-
Dimitris Nakos, Founder and Owner of
Ammos Estiatorio
https://ammosnewyork.com/

“Whom You Know has done an amazing job of featuring our company over many years [seven]. Peachy has worked tirelessly to create a well-curated selection of topics and brands that are clearly of relevance to her growing audience of readers. Her articles are filled with great insights based on first-hand experience. She does her research, knows her business and is a pleasure to work with!”

-David Sasuga, Owner of Fresh Origins Microgreens
www.FreshOrigins.com

"Peachy Deegan has the pulse of the nation and highlights exceptional opinion leaders in more than 23,000 inspiring and entertaining posts. Her 100,000 twitter followers are a true testimony to Peachy’s ability to inspire, motivate and entertain. She is a feminine force to be reckoned with and an exemplary example of an influential voice in today’s world."

-Mica Mosbacher, author of the new book The Hurricane Factor: Stormside Patriots and tv political commentator

"It was an honour to be chosen for Movers and Shakers by Peachy Deegan. The questions in the interview were intelligent and insightful and I thoroughly enjoyed answering them. The reaction to the interview has been overwhelmingly positive and has helped bring my art practice to a wider audience."
-Damien Flood, Internationally Acclaimed Artist
http://www.damienflood.ie/

"We were so fortunate to hit Peachy’s radar. Her review of our Warmies was spot-on and came at a great time in our company’s early history.
Peachy has such a strong relationship with her readers. She provides honest and real comments; she is truly a trusted source in a very large circle
of consumers."
-Scott Wehrs
President
Intelex U.S.A.
http://www.intelexusallc.com/

"We at Primola love working with Whom You Know and are proud to have been a highly-ranked Manhattan restaurant by Peachy Deegan since 2012, and are featured seasonally. We appreciate the fantastic work Peachy does highlighting our cuisine with her sublime writing style and the whole neighborhood of the Upper East side. Also, we are glad that she has started a Made in Italy column! If you have the opportunity to be considered for review, we'd highly recommend working with her."
-Giuliano Zuliani, Owner of Primola Restaurant
https://www.facebook.com/Primola-Canaletto-restaurants-NYC-135616799831091

"
Peachy Deegan is a gem. She is wonderful to feature our Irish brands in 'Whom You Know'! The articles are beautifully and passionately presented, bringing products and brands to life, making both relevant and fun for her many faithful followers to read. I am immensely proud for our hand-crafted products to be included in this venue!"

-
Bill Follett
President, Belleek Group North America
www.Belleek.com

"As you know from my past features, Peachy Deegan and I were in the same class at Boston College prior to either of us becoming entrepreneurs. When we played together on the BC Alumni softball team in Central Park years ago, she mentioned she could not find a great dentist in Manhattan and could often be found networking on her phone in the outfield hiding from the ball. She was my second patient ever in 2006 when I opened my dental practice; I was one of the first sponsors on Whom You Know and the first Mover and Shaker featured in 2009 and have worked with her continuously since. She's even talked her friends that are doctors into being my patients, and they subsequently send their hospital colleagues. I don't know anyone that is as great of a networker and writer as Peachy, nevermind that she is upstanding and always good for her word. Cosmopolitan Dental is so happy to be in the company of the caliber of major brands she works with today, and although she will tell you a million ways to get your teeth dirty between Peachy's Picks, Terrific Takeout and Peachy's Pantry, Peachy Deegan will tell you there is only one way to get your teeth clean!"
-Dr. Garo Nazarian, Founder and Owner of Cosmopolitan Dental
http://cosmopolitandental.com/